The Puzzle of the Pill: Loyal & LOY-002
In which a veterinarian creates a constraint satisfaction problem to indulge his potentially inadvisable level of curiosity
Loyal is a San Francisco-based clinical-stage biotechnology company founded in 2019 by CEO Celine Halioua. They’re developing the first drugs explicitly intended to extend the healthy lifespan of dogs. The parent entity is called Cellular Longevity, and the broader thesis is “dogs first, humans later.” Not a bad plan, as dogs are a stronger translational model for aging humans than mice.1
And it would seem that Ms. Halioua2 and her team are onto something. In February 2026, Loyal announced a $100 million Series C led by age13, with participation from Baillie Gifford, bringing total investment in the company to over $250 million. They’ve got a number of drugs in development to justify that funding.
LOY-001 targets large and giant breed dogs, which are known to have shorter lifespans. It’s a long-acting injection administered every three to six months by a veterinarian, targeting the overexpression of insulin-like growth factor 1 (IGF-1) believed to drive accelerated aging in large dogs. In 2023, the FDA’s Center for Veterinary Medicine accepted Loyal’s Reasonable Expectation of Effectiveness application for LOY-001. A first for any longevity drug, in any species.
LOY-002 is a daily, flavored tablet for senior dogs that targets metabolic dysfunction as an underlying mechanism of aging. In February 2025, the FDA also accepted the RXE for LOY-002. In December 2025, the FDA accepted the Target Animal Safety submission. That’s two of three major technical sections complete for Expanded Conditional Approval. The company’s STAY study enrolled over 1,300 dogs across 70 independent veterinary clinics and is expected to last four years. It is, according to Loyal, the largest clinical trial in the history of veterinary medicine by enrollment. The company describes the drug as a caloric restriction mimetic.
LOY-003 targets large dogs via a daily oral pill. Loyal identified it as CRN019414 in a blog post announcing their partnership with Crinetics Pharmaceuticals. It’s a nonpeptide somatostatin receptor type 2 agonist, targeting the same GH/IGF-1 pathway as LOY-001, different delivery vehicle.
Interestingly, they’ve never disclosed the active pharmaceutical ingredient for either LOY-001 or LOY-002. Even the molecular targets have been kept somewhat vague. LOY-003 is the only compound they’ve named.
They raised nine figures, now a quarter of a billion dollars, without publicly revealing the drug and only hinting at the mechanism of action? For somebody like me, the opacity raises the eyebrows a bit. Which is to say that it sparks a dopamine-rich hyperfocus for being a fun puzzle to solve.
Disclaimer
I’ve spent some time trying to uncover or figure out the nature and identity - or approximations thereof - of Loyal’s LOY-001 and LOY-002.
I have no insider knowledge, I have no financial interest, and no connection besides a free pair of socks they gave away at a veterinary conference.5 What I do have is intense curiosity, a veterinary degree, an internet connection, and dubious self-regulatory mechanisms.
But I want to make it absolutely clear at the outset that everything that follows is speculation. I own a small animal hospital in Chadds Ford, Pennsylvania. I have no consulting relationship with the company, I have no access to proprietary data, and, other than Dr. Brennan McKenzie, whose reputation in veterinary medicine precedes his connection with Loyal, I doubt that I could reliably pick any member of their leadership team out of a lineup.
This article is an intellectual exercise. It is a statement of opinion, not fact, though I’ve tried to base it on a collection of facts. I’m just a nerd who went on a research bender, trying to assemble the pharmacological puzzle from publicly available sources like patent filings, peer-reviewed literature, FDA regulatory documents, the company’s own press releases and published research, and the leadership’s public writings and interviews.
I am very much not claiming to know what LOY-002 contains. I’m reasoning, in print, towards a hypothesis.
Loyal has stated that they cannot disclose the active ingredient prior to FDA conditional approval for intellectual property reasons. I respect that decision. On the outside chance I’m right6 about what follows, it changes nothing about the regulatory process or clinical evidence they’re generating.
Nothing in this article constitutes or should be interpreted to constitute medical advice, investment advice, or a recommendation to prescribe, compound, or administer any medication on- or off-label to any animal.
There, now we’ve finished the CYA bit. So down the rabbit hole we go.
“But I don’t want to go among mad people,” Alice remarked.
“Oh, you can’t help that,” said the Cat: “we’re all mad here. I’m mad. You’re mad.”
“How do you know I’m mad?” said Alice.
“You must be,” said the Cat, “or you wouldn’t have come here.”
—Lewis Carroll, Alice’s Adventures in Wonderland
LOY-001: Quick and Easy
I’m going to focus on LOY-002, since it poses the more interesting mystery. LOY-003 has been disclosed for years. LOY-001 is strongly suggested to be a somatostatin-pathway drug. Loyal has confirmed it targets the same pathway as LOY-003, which is CRN01941, a somatostatin receptor agonist.
I think LOY-001 is something near to octreotide, along with a wrinkle that makes the dosing extremely long-acting and/or possibly a novel formulation or depot technology. It might be an antisense oligonucleotide that knocks down IGF-1 directly. The three-to-six-month dosing interval probably means it’s not plain octreotide.
See? Done. This could’ve been a much shorter essay.
Loyal CEO, Celine Halioua
I didn’t set out to profile the company’s CEO, but a substantial amount of communications about the company come directly from her personal pages. And I wanted to include a few paragraphs about her because it proved more important, and interesting, than I’d anticipated.
CEO Celine Halioua7 is precise, deliberate, and, for the most part, candid in her public persona. She shares company milestones alongside deeply personal disclosures on Twitter/X. She talks about her OCD medication, her rescued dog’s abuse history, and her Series B funding failures.8 And it’s obviously meant to work as a marketing ploy, but, looking closely, I’d have a hard time condemning her for it.
She says she’s spent hundreds of hours studying Silicon Valley communication strategy at what amounts to a mechanical level and she openly admits to engineering her public persona. That might give some folks pause, but I think that’s just what a good leader does in that position. My skin crawls at the leaders who try to make the world believe that they’re naturals. That the facility they have in something was the result of a deity, cosmic beneficence, or a magic wand. That strategy is nothing more than fairy-tales-as-emetics for me.
Ms. Halioua, by contrast and to her credit, is candid about the effort, revealing what I’ll call a precisely measured amount of genuine humility. She studied strategies and mechanisms in order to develop a skill crucial for her job? She learned and practiced to get better at something? How. Dare. She.
Moreover, she writes well, and I say that as a person who spends a lot of time trying to write well. I’m admittedly inclined to overweight the value of that, but being intentional about what you put in print is something for which I both endeavor and advocate. She’s written “I write to synthesize my thoughts” and “don’t build boring shit” in her blog posts, which cover monoclonal antibodies, personal trauma, communications, and startup operations. I’m not sure I could recognize Ms. Halioua if she sat next to me on a park bench, but in the writing I see a familiar mind: intense, curious, and purposeful.
This is all to say that after reading a lot of what this person has written, I’ve come to respect them a great deal.
When I use a word,” Humpty Dumpty said, in rather a scornful tone, “it means just what I choose it to mean — neither more nor less.”
“The question is,” said Alice, “whether you can make words mean so many different things.”
“The question is,” said Humpty Dumpty, “which is to be master — that’s all.”
—Lewis Carroll, Through the Looking-Glass
The Pharmacological Fingerprint of LOY-002
LOY-002 is where things get interesting, because Loyal has simultaneously told us a great deal and almost nothing. What they have disclosed, across interviews, blog posts, press releases, and published research, creates a delightfully tight set of pharmacological constraints.9
Think of it as a game of “Guess Who?” or one of those logic puzzles you might’ve done as a kid. What your nerdier friends may refer to as a constraint satisfaction problem. Except instead of being given a list of statements, you get to compile them yourself.
Here’s what I’ve found:
The drug is a caloric restriction mimetic. Ms. Halioua has described it as “delivering the benefits of caloric restriction through a pharmaceutical drug, without weight loss or appetite suppression.” She’s also said, in a tweet responding to questions about GLP-1 agonists, that “you can hit further downstream the caloric restriction pathway to get the metabolic aging benefits without appetite suppression - that’s our focus for now.”
The word downstream is helpful in those sentences. It say the drug isn’t acting on appetite or food intake, it’s acting on whatever the cell does after caloric restriction signals arrive. That’s more than marketing copy, it’s an insight into the mechanism.
Ms. Halioua has explicitly ruled out rapamycin and metformin. Those are the two most prominent longevity candidates in public discourse. Crossing them off narrows the field considerably.
She’s also written that, “to maximize benefit, aging drugs need to become boring.”
LOY-002 has been described as targeting “a mechanism that, in mice and humans, has shown notable improvement in cognitive function and all-cause mortality.” While this is not a direct quote, it comes from an interview published in a legitimate trade publication and it is a precise statement. And it’s one on which I’m going to lean, because it not only requires that LOY-002 has shown improvement in cognitive function and all-cause mortality, but also that the compound has rodent data and human data. It’s not necessarily from aging-specific trials, but from somewhere in the published literature.
LOY-002 uses “a slightly different mechanism” from LOY-001 and LOY-003. Since both of those target the GH/IGF-1 axis (LOY-001 via injection, LOY-003 via oral somatostatin receptor agonism), this definitively separates LOY-002 from the somatostatin/GH/IGF-1 pathway and, I think, places it in the metabolic and energy-sensing domain.
In a dvm360 interview, Ms. Halioua characterized LOY-002 as “a little bit more of a reversal mechanism. It’s not going to make a 10-year-old dog a puppy, but we’ve seen a rescuing in age-related functional decline in dogs that have been treated with this drug.”
And the safety data: no clinically significant adverse events at 1×, 3×, and 5× dosing in a standard Target Animal Safety study, plus field safety data from over 400 senior companion dogs in the STAY trial. The FDA accepted this package in December 2025. That’s an unusually clean safety profile for a chronic-use drug.
The drug is formulated as a daily beef-flavored oral tablet for dogs 10 years and older, weighing at least 14 pounds. It is, per the company’s description, intended for virtually the entire senior dog population aside from the very smallest patients.
So here’s the constraint set. Whatever LOY-002 is, it must be:
A caloric restriction mimetic
Stated
Active downstream in the CR pathway, not via appetite or intake
Stated
Not rapamycin, not metformin
Stated
Not a somatostatin analog or GH/IGF-1 axis drug, a different mechanism from LOY-001/003
Stated
Supported by cognitive function data, in rodents and/or humans
Inferred secondhand, stated by journalist in interview
Supported by all-cause mortality data in humans
Stated
Safe at five times the intended dose in dogs, with no clinically significant adverse events in 400+ dogs
Stated
An oral tablet, likely generic or off-patent
Stated, and consistent with the company’s IP strategy
Not causing weight loss or appetite suppression
Stated
That is actually a pretty narrow pharmacological window. And it only took reviewing a few dozen blog posts, tweets, interviews, and press releases to get there.
“Contrariwise,” continued Tweedledee,
“if it was so, it might be; and if it were so, it would be; but as it isn’t, it ain’t.
That’s logic.”
—Lewis Carroll, Through the Looking-Glass
The PPAR Trail
In February 2026, coinciding with Loyal’s Series C announcement, Rapamycin Longevity News published a post stating that “industry analysis of the drug’s physiological effects points to the Peroxisome Proliferator-Activated Receptor (PPAR) pathway, specifically involving PPAR-γ modulation or Selective PPARα Modulator (SPPARMα) activity.” This fairly briefly article helped me to narrow the search considerably.
I’d describe that article as industry analysis, not insider disclosure. Their post is at least as speculative as my article. But it does align remarkably well with the pharmacological evidence, and it narrows our search to a specific family of nuclear receptor agonists.
Peroxisome proliferator-activated receptors (PPARs) are nuclear transcription factors that function as lipid sensors and metabolic regulators. There are three isoforms: PPARα (predominantly expressed in liver, heart, kidney, and muscle; governs fatty acid oxidation), PPARγ (adipose tissue, immune cells; governs insulin sensitivity and inflammation), and PPARδ/β (broadly expressed; governs fatty acid catabolism and energy homeostasis). They are master regulators of metabolic gene expression.
Think of these three as three regional managers for a company that runs fuel logistics.
PPARα is the operations manager at the power plant (liver, heart, muscle). When fuel shipments arrive (fatty acids), the PPARα decides how fast to burn them. High demand? Light the furnaces. Low supply? Burn the reserve fuel stocks.
The PPARγ handles warehousing and human resources. How much fuel to store, where to put it, and keep the immune cell workforce from striking or rioting. When this is working, your inventory is organized and labor relations are smooth; that’d be your insulin sensitivity and inflammation control.
PPARδ/β is the roving efficiency consultant who works across every department. They’re less specialized, but everywhere at once. They’re tweaking fuel usage and make sure no division is wasting fuel or running a deficit.
The connection between PPARα and caloric restriction (CR) is not speculative. It is established in the peer-reviewed aging biology literature. A foundational finding, one that anyone doing serious work in this space would know, is that approximately 19% of all hepatic gene expression changes induced by caloric restriction are PPARα-dependent. In PPARα-null mice, those CR-mediated metabolic adaptations are abolished entirely. Caloric restriction upregulates PPARα expression in heart and liver tissue, increasing lipid utilization and enhancing fatty acid β-oxidation. A 2020 review in Cells stated the relationship explicitly: “Ligands of PPARα have been proposed to serve as mimetics of CR.”
That’s not “may be associated with,” that’s “a proposed class of caloric restriction mimetics.”
And Loyal’s own published research keeps pointing at the same metabolic targets. McKenzie et al. (2025) demonstrated that insulin increases, adiponectin decreases, and free fatty acid accumulation all correlate with frailty in 451 companion dogs. And explicitly noted that adiponectin signals through PPARα to increase fatty acid oxidation and reduce inflammation. Peloquin et al. (2024) showed that saturated fatty acid concentrations predict insulin sensitivity in dogs. McKenzie et al. (2024) demonstrated that a high-fat diet induces metabolic changes mimicking natural aging.
These papers all highlight biomarkers like hyperinsulinemia, dyslipidemia, elevated free fatty acids, decreased adiponectin. And those biomarkers all squarely in the therapeutic wheelhouse of a PPARα agonist.
“Who in the world am I? Ah, that’s the great puzzle!”
—Lewis Carroll, Alice’s Adventures in Wonderland
Where the Path Led: Fenofibrate Esters
If you’re a veterinarian reading this, you’ve might’ve already guessed where I’m going. If you’re not, let me introduce you to a drug that’s been sitting quietly on pharmacy shelves since the 1970s.
Fenofibrate is a fibric acid derivative with fenofibric acid as its active metabolite. It’s a PPARα agonist, the most widely prescribed one in human medicine. Fenofibrate is used to treat hypertriglyceridemia and mixed dyslipidemia, typically as adjunctive therapy with statins. It’s been generic since 2005, available from over 30 manufacturers worldwide, in tablets and capsules ranging from 35 to 160 mg.
It is also already used, off-label, in veterinary medicine. It is a drug with which the veterinary community has experience, on which the FDA has decades of safety data, and that VCA Animal Hospitals lists as a standard veterinary medication for canine hyperlipidemia.
Fenofibrate is the most commercially available and familiar delivery vehicle among multiple possible prodrugs. Choline fenofibrate already received its own FDA approval as a distinct product. Lv et al. (2020) synthesized seven fenofibric acid ester prodrugs (JF-1 through JF-7).
All of the evidence I'll present below applies to fenofibric acid as the active metabolite. Most of the published data comes from studies using fenofibrate because that's the prodrug with forty years of clinical history. But the pharmacological logic of the CR mimetic activity, the cognitive data, the mortality signal, and the canine safety profile is driven by fenofibric acid at the PPARα receptor, not by which ester shell delivers it. Whether LOY-002 is fenofibrate itself, a novel ester with superior bioavailability, or something else in the fenofibric acid family, the constraint analysis points to the same place.
Criterion #1: Caloric restriction mimetic
Technical: PPARα ligands, including fenofibrate, have been explicitly proposed as CR mimetics in reviews. The mechanistic overlap with caloric restriction is well-established at the transcriptomic level: mediated through shared AMPK, SIRT1, and mTOR signaling cascades. A separate patent filing (US20160186257, unrelated to Loyal) identified bezafibrate, a pan-PPAR agonist in the same fibrate class, as the most effective CR mimetic in comprehensive gene expression analysis.
Translation: Fenofibrate tricks the body into thinking it’s on a diet, at the cellular level, without actually reducing food intake. The molecular machinery it activates overlaps so heavily with what caloric restriction activates that researchers have literally published papers calling drugs in this class “caloric restriction mimetics.” A different patent, unrelated to Loyal, even identified a close chemical cousin of fenofibrate as the single best pharmaceutical match for the gene expression signature of caloric restriction.
Criterion #2: Downstream mechanism, no appetite suppression
Technical: Fenofibrate acts at the nuclear receptor level, modulating gene expression in hepatocytes and other target tissues. No mention of the appetite circuits. It doesn’t suppress food intake. It activates the same downstream metabolism that caloric restriction activates (namely fatty acid β-oxidation, ketogenesis, insulin sensitization) without the upstream signal of reduced caloric intake.
Translation: Fenofibrate works inside the cell, flipping metabolic switches in the liver and other organs, not in the brain's hunger center. It never tells the dog to stop eating. Instead, it goes straight to the cellular machinery that caloric restriction eventually activates anyway, burning fat, making ketones, improving insulin response, by direct mechanism. All of the metabolic benefits, none of the begging at an empty bowl.
Criterion #3: Not rapamycin, not metformin
Technical: It is neither of those things. I am offering no citations for this.
Translation: Duh.
Criterion #4: Different mechanism from LOY-001/003
Fenofibrate operates through PPARα-mediated transcriptional regulation. It has nothing to do with somatostatin receptors or direct IGF-1 suppression. It does, however, attenuate IGF-1 receptor signaling downstream, cancer biology studies have shown it suppresses IGF-1R-mediated cellular responses through inhibition of IRS-1, ERK, Akt, and GSK3β phosphorylation. This is a mechanistically distinct pathway from the direct IGF-1 level reduction that LOY-001 and LOY-003 pursue. Different mechanism but with similarly broad relevance to aging.
Translation: Fenofibrate doesn't work anything like Loyal's other two drugs. LOY-001 and LOY-003 reduce the amount of a growth hormone signal (IGF-1) circulating in the body, effectively turning down the output at the source. Fenofibrate leaves the signal alone but makes the cells less reactive to it, like putting earplugs on the listener instead of muting the speaker. Same net effect on aging pathways, completely different mechanism, which is more or less exactly what Loyal said LOY-002 would be.
Criterion #5: Cognitive function data in rodents
If the fenofibric acid hypothesis is correct, we would expect to find evidence of the cognitive benefit in published literature. And we do.
At least four rodent studies demonstrate fenofibrate’s cognitive benefits. It prevents post-ischemic memory impairment (dose-dependently reducing infarct volume), preserves hippocampal neurogenesis, reverses high-fat-diet-induced cognitive deficits via the PGC-1α/irisin/BDNF pathway, and improves post-operative cognitive dysfunction after isoflurane anesthesia. The Alzheimer’s Drug Discovery Foundation’s Cognitive Vitality report attributes fenofibrate’s neuroprotective properties to anti-inflammatory, antioxidant, and vascular barrier protective effects through PPARα activation.
An interview with Ms. Halioua published in a trade publication characterized LOY-002 as targeting a mechanism with demonstrated improvement in cognitive function and all-cause mortality in mice and humans. That phrasing is the journalist's, not a direct quote, so I'm not treating it as a hard constraint. But it is consistent with what the PPARα mechanism would predict.
Translation: Fenofibrate doesn't just help metabolism, it protects the brain. At least four studies in mice and rats show it prevents memory loss after stroke, keeps the hippocampus generating new neurons, reverses the cognitive fog caused by high-fat diets, and sharpens thinking after anesthesia. The Alzheimer's Drug Discovery Foundation has specifically flagged it as neuroprotective.
Criterion #6: All-cause mortality data in humans
A Korean cohort study of 10,114 diabetics found fenofibrate use associated with all-cause mortality with a hazard ratio of 0.437. That’s a 56% relative risk reduction, with longer use showing even stronger effects. A separate Korean general-population study of 555,672 individuals with high triglycerides showed all-cause mortality HR of 0.826 for fenofibrate add-on therapy, dropping to 0.618 with a year or more of use. Post-hoc analysis of the ACCORD Lipid trial found significant mortality reduction (HR 0.57) in early-diagnosed hyperlipidemia. The ACCORDION legacy study showed sustained benefit (adjusted HR 0.65, P = 0.02). A Korean national cohort of 110,723 matched pairs found fenofibrate users had HR 0.716 for all-cause death.
Translation: people who take fenofibrate die less, and the studies are considerable. Across multiple large human populations, tens of thousands to over half a million patients, fenofibrate users had significantly lower rates of death from all causes. The biggest signal showed a 56% reduction in mortality among diabetics. The consistent finding across every study is the same: take it longer, do better. These aren't just rodent models anymore. These are real humans, in real healthcare systems, over years.
Criterion 7: Safety in dogs at up to 5× dosing
This is where fenofibrate separates from the field.
Miceli et al. (2021) published a prospective randomized trial of 124 dogs with severe hypertriglyceridemia, treated at 10 mg/kg once daily. The result: 85.9% triglyceride normalization. Adverse effects: 3% experienced mild diarrhea. No significant adverse effects. Munro et al. (2021) at UC Davis studied micronized fenofibrate in 10 hyperlipidemic dogs over a dose-escalation protocol. Quiet demeanor and firm stools in one dog were the only reported adverse reactions. Crakes et al. (2021) demonstrated safety in diabetic dogs with maintained body weight and improved gut barrier function. O’Kell et al. (2025) did the same with naturally occurring diabetes mellitus. The fatal toxicity dose in dogs exceeds 4,000 mg/kg, providing an enormous therapeutic margin.
Loyal’s product brief states the active ingredient has “extensive” prior safety data across studies lasting four weeks to one year in over 400 dogs, with no clinically significant adverse events at 1×, 3×, and 5× expected doses.
Those study durations (four weeks, thirteen weeks, one year) are the standard regulatory toxicology study intervals required for original FDA drug approval in any species. Which means that, whatever this drug is, it went through the full gauntlet of FDA-mandated preclinical toxicology in dogs when it was first approved for human use. Fenofibrate, as a human drug approved in the 1970s, would have required exactly these studies. Those datasets already exist. They would constitute the kind of “extensive evidence” that a startup could reference, even a well-funded one, without having to generate all of it de novo.
I’ll talk more about the alternatives later, but this is where fenofibrate separates from the pack.
Translation: Fenofibrate is almost comically safe in dogs. Multiple studies, over a hundred dogs in one trial alone, show it works beautifully for its intended metabolic effects with virtually no side effects. The worst reported reaction across all the studies was one dog who got quiet and had poops. The lethal dose is so astronomically high it's practically irrelevant. Moreover, because fenofibrate was originally approved for humans in the 1970s, the FDA already required extensive safety testing in dogs as part of that process. Those studies, four weeks, thirteen weeks, one year, already exist in a filing cabinet somewhere. A startup with good lawyers wouldn't need to reinvent that wheel. They'd just need to patent a new use for it.
Criterion 8: Oral tablet, generic, off-patent
Fenofibrate is available as an oral tablet. It’s been off-patent for over two decades, and it’s manufactured by more than 30 generic companies worldwide. This makes it ideal for a method-of-use patent strategy: you patent the novel veterinary indication (canine lifespan extension) rather than the compound itself.
Translation: You can't patent fenofibrate, that ship sailed in the 1900s. But you absolutely can patent a new use for it, like "this old cholesterol drug extends dogs' lives." That's your intellectual property claim. And it explains the secrecy reasonably well: the moment you tell the world what's in the pill, every veterinarian in the country can prescribe it off-label before your patent is even enforceable. If you've raised a quarter billion dollars, you probably want to keep your mouth shut until the paperwork is locked down.
Criterion 9: No weight loss or appetite suppression
This is, I think, my hypothesis’s weakest point.
In obese beagles, fenofibrate caused a small (3%) but statistically significant weight loss over 15 days that reversed upon cessation. In rodent models, higher doses clearly reduce food intake and body weight. However, in diabetic dogs at ideal body condition, “all dogs maintained their body weight and ideal body condition score” during treatment.
The resolution to this contradiction is likely dose-dependent. LOY-002 is intended for metabolic modulation in aging, not aggressive lipid-lowering in hyperlipidemic patients. A lower dose optimized for metabolic signaling rather than triglyceride normalization might produce clinically negligible weight effects. Loyal’s claim may be precisely calibrated to the dose they’re using.
Translation: Fenofibrate can cause minor weight loss at higher doses, obese beagles lost about 3% in one study, and rodents on big doses clearly ate less. But dogs at healthy weight held steady. The likely explanation is straightforward: crank up the dose and you get weight effects; dial it down to the sweet spot for anti-aging metabolic tuning rather than aggressive cholesterol-lowering, and the weight needle probably doesn't move. Loyal would know exactly where that line is. They've had 1,300 dogs to figure it out.
What I tell you three times is true.
—Lewis Carroll, The Hunting of the Snark
The Paper Trail
Cellular Longevity Inc. was granted U.S. Patent Application 18/621,541 on December 10, 2024, titled “Method of increasing lifespan in mammals.” It was filed under Track One prioritized examination. The full claims remain inaccessible through free patent databases—likely due to indexing lag for recently granted patents, or possibly because Loyal exploited non-publication options to keep the filings confidential until grant.
CBInsights’ automated topic classification reveals five keywords assigned to this patent: Fatty acids. Prodrugs. Diabetes. Vegetable oils. Nutrition. Now, that’s probably just a piece of machine learning software10 assigning keywords based on patent data and metadata. But it’s remarkable how well it fits.
Now consider the following:
Fenofibrate is a textbook prodrug. It has zero pharmacologic activity in its administered form. It is completely hydrolyzed by tissue and plasma esterases to its active metabolite, fenofibric acid. No unchanged fenofibrate is detectable in plasma. The “prodrugs” tag alone eliminates pioglitazone (active parent compound), acarbose (not a prodrug), octreotide (not a prodrug), and most other candidates.
Fenofibric acid is a fibric acid derivative. Literally a propanoic acid ester, a fatty acid. The “fatty acids” tag matches the drug’s chemical classification, its mechanism (PPARα-mediated fatty acid β-oxidation), and the metabolic pathway it modulates.
Fenofibrate esters are extremely lipophilic. Fenofibrate’s log P is 5.24. Its aqueous solubility is 0.263 µg/mL, which is essentially insoluble. Commercial fenofibrate formulations require lipid-based excipients to achieve adequate bioavailability using things like soybean oil, soya lecithin, and related vegetable-derived carriers are already standard in existing formulations. The “vegetable oils” tag reads like an excipient disclosure for a lipid-based oral delivery system. For a beef-flavored daily tablet, you’d need this kind of formulation work.
Diabetes fits fenofibrate’s established clinical role managing diabetic dyslipidemia.
Nutrition aligns with its labeling as adjunct to dietary therapy and Loyal’s framing of LOY-002 as a pharmaceutical alternative to caloric restriction.
Three total patents have been filed by Cellular Longevity Inc. The top topics across all filings, diabetes, companion dogs, prodrugs, all seem reinforce the fenofibrate hypothesis rather than diluting it.
The Elimination Round
This wouldn’t be worth much if I only argued for fenofibrate. This will review the reasons why I concluded on fenofibrate and not something else.
Octreotide and other somatostatin analogs are almost certainly LOY-001’s mechanism and definitively LOY-003’s (Crinetics’ CRN01941). Having LOY-002 also be a somatostatin analog would be redundant and directly contradicts Ms. Halioua’s statement about a “slightly different mechanism.” A 2005 study by Robben et al. found octreotide didn’t suppress basal GH levels in healthy fasting dogs—undermining the core rationale. Chronic somatostatin analogs carry a 10–63% incidence of gallstones and 57–68% GI adverse event rates in oral formulations (Mycapssa Phase 3 data). That’s incompatible with “no clinically significant adverse events” at 5× dosing. And oral peptide octreotide requires specialized liquid-filled capsule technology with approximately 0.7% bioavailability, fasting administration, and doses 200× the injectable equivalent. Good luck making that into an affordable beef-flavored tablet.
Acarbose deserves more respect than it usually gets in these conversations. It’s the only drug to show robust lifespan extension in the NIA Interventions Testing Program—16–22% median lifespan increase in male mice across multiple sites. It’s an oral tablet, generic, off-patent, and already used in veterinary medicine for diabetic dogs. Those are real credentials.
But acarbose is not a PPAR agonist. It has no “Prodrugs” or “Fatty acids” patent tag relevance. Its cognitive function data is indirect and limited to combination studies and hepatic encephalopathy patients rather than direct neuroprotection. And its GI side effect profile in dogs is a pharmacological inevitability of its mechanism: block carbohydrate absorption, and undigested carbohydrate reaches the colon, where it ferments. Nelson et al. (2000) found that 60% of dogs developed semisoft to watery feces. You cannot dose-optimize your way around the fundamental mechanism of action. Loyal’s “no clinically significant adverse events at 5× dosing in 400+ dogs” is very hard to reconcile with a drug that gives three in five dogs loose stool at therapeutic doses.
Pioglitazone targets PPARγ rather than PPARα, is not a prodrug, caused cardiac hypertrophy and thoracic effusion in dogs during preclinical safety testing, and carries a black box warning for congestive heart failure in humans. It also commonly causes weight gain—which is the wrong direction for a longevity intervention. It’s currently in the NIA ITP 2022 cohort, with results pending. If those results are spectacular, I’ll revisit. Until then: no.
Pemafibrate is the SPPARMα specifically named in the Rapamycin News analysis. It’s an elegant molecule, but it has no published dog safety data whatsoever, is approved only in Japan, and its landmark PROMINENT cardiovascular outcomes trial—the one designed to validate the SPPARMα concept in human clinical endpoints—failed its primary endpoint. That’s not a death blow for the molecule, but it means there’s no published mortality or cognitive benefit data to match Loyal’s stated criteria.
Bezafibrate is a pan-PPAR agonist in the same fibrate class and was actually identified as the most effective CR mimetic in comprehensive gene expression analysis. It’s a credible molecule. But it has less canine safety data than fenofibrate and isn’t marketed in the United States, making it fit the marketing claims less precisely. For a company planning to launch a commercial veterinary product through U.S. distribution channels, sourcing a non-U.S.-marketed API adds unnecessary complexity.
“I can’t believe that!” said Alice.
“Can’t you?” the Queen said in a pitying tone. “Try again: draw a long breath, and shut your eyes.” Alice laughed. “There’s no use trying,” she said; “one can’t believe impossible things.”
“I daresay you haven’t had much practice,” said the Queen.
“When I was younger, I always did it for half an hour a day. Why, sometimes I’ve believed as many as six impossible things before breakfast.”
—Lewis Carroll, Through the Looking-Glass
Of Course, I Could Be Wrong
A constraint satisfaction problem only works if I steelman my own arguments.
The lifespan gap. The strongest evidence against fenofibrate is the absence of formal lifespan extension data in normal aging mice. Fenofibrate has never been tested in the NIA Interventions Testing Program. No published study demonstrates extended median lifespan in healthy wild-type mice. If Ms. Halioua’s interview-but-not-quoted reference to improvement in all-cause mortality in mice refers to a formal longevity study, this would need to be Loyal’s proprietary data, which weakens the hypothesis by requiring an assumption of unpublished evidence.
Alternatively, the “mice” reference may encompass disease-model mortality reductions; fenofibrate reduced mortality by 80% in a Japanese encephalitis model and extended survival in cachexia models. The language is ambiguous enough to accommodate either interpretation.
The weight question. I addressed this above, but it remains a genuine vulnerability. If any well-powered canine study shows significant weight loss at LOY-002’s dose, the hypothesis has a problem.
The secrecy question. If LOY-002 is just fenofibrate, a generic drug any veterinarian could prescribe off-label tomorrow, then why the elaborate secrecy? Two possible answers.
First, the method-of-use patent strategy requires maintaining confidentiality until the patent is granted and enforceable; disclosing the compound prematurely could jeopardize the IP protection that justifies $250 million in investment.
Second, Loyal may be using a proprietary fenofibrate formulation. A novel prodrug variant, a lipid-based delivery optimization, a specific dose-finding innovation that isn’t plain fenofibrate-in-a-tablet. The patent’s “prodrugs” and “vegetable oils” tags are consistent with this conclusion as well. The answer might not be “fenofibrate” so much as “fenofibrate with a twist.”
The possibility that I’m just wrong. The compound could be something else. It could be a genuinely novel molecule, a repurposed drug outside my analysis, a combination formulation, or just something I missed. Loyal has smart people, significant capital, and access to compound libraries and research I don’t have. Honesty - and humility - mandate acknowledging that the puzzle might have pieces I can’t see, solve, or discern.
“Now, here, you see, it takes all the running you can do, to keep in the same place. If you want to get somewhere else, you must run at least twice as fast as that!”
—Lewis Carroll, Through the Looking-Glass
So What?
The embarrassing part of this story is that, until recently, I didn’t think very much of what the folks at Loyal (Loyalists?) had built.
I don’t think I was quite as bad as the some of the anonymous bloggers whose criticisms largely amounted to “this hasn’t been proven yet” (duh) and “this is only good if it improves quality of life” (also duh, but it ignores the fact that these things aren’t accomplished and demonstrated in a single gust of effort). Still, I found the caginess and opacity annoying at best and suspicious at worst. I thought it was a gimmick, intended to add an air of mystique and sophistication to act as a kind of capital yeast11 for a mediocre or even unworkable idea. I was even a bit cynical about Ms. Halioua’s Entrepreneurial Spirit Award at the Feather in Her Cap event this year. “They’ve just raised a lot of money and published a few studies,” I thought, “so what?” The whole thing felt a bit too much like Theranos to me.
But my suspicions have resolved to garden variety skepticism. I’ve spent a few hours really digging into this, and, well, I don’t think it’s a gimmick anymore. Reading more of what Ms. Halioua has written, I’m increasingly impressed with the “safe, well understood, cheap, small molecule generics” approach12. I think the Loyalists might legitimately be onto something, and it’s possible that something is a 50-year-old generic medication that’s been sitting in pharmacies since the Ford administration.
It’s less anticlimactic than it sounds.
The author Terry Pratchett, in The Science of Discworld, wrote that, “science is not about building a body of known ‘facts.’ It is a method for asking awkward questions and subjecting them to a good reality-check, thus avoiding the human tendency to believe whatever makes us feel good.”
The drug may have been there for half a century, waiting for someone to ask an awkward question.
It means Loyal’s contribution isn’t the molecule but rather the novel application of the molecule. It’s the regulatory pathway, the clinical trial infrastructure, the 1,300-dog STAY study, the proof that you can take “aging” to the FDA as a treatable condition and get them to agree. If Loyal has something real, the process is the triumph. A novel paradigm rather than a novel pill.
And it means that veterinarians like are going to need to learn a new vocabulary. We maybe knew fenofibrate for off-label use after lipid panels and pancreatitis risks. We don’t know it as a longevity drug. We don’t think about PPARα activation as a caloric restriction mimetic, because until this decade it wasn’t. And you’d have to be deep in the research to find it. We don’t prescribe medications to slow aging, because until now, there hasn’t been an medication approved for doing so.
If it works, it’s going to change things in the hospital.
There’s a twelve-year-old intact male Labrador retriever patient named Cody who still thinks he’s a puppy, except on the mornings when he can’t get up from the floor without help and NSAIDs.
There’s a fourteen-year-old spayed female mix named Sadie who’s losing the plot a bit, circling, staring at walls, forgetting where she is.
There’s an eleven-year-old neutered male Beagle named Maple13 whose bloodwork is slowly, predictably drifting into that metabolic no-man’s-land of insulin resistance and rising triglycerides that precedes the avalanche of age-related disease.
I think about them when I read about LOY-002 and imagine what it could be. I think about what it would mean to have one more thing that could help buy George a few more mornings of getting up, that could keep Sadie oriented in her own house for another year, that could flatten Maple’s metabolic trajectory before it steepens to an asymptote I cannot treat.
I’m as skeptical, impatient, and unrelenting as you’d expect from a man who has spent most of his waking hours for the last decade standing between his patients and the pathologies that come for them.
Sometimes I fight to win, sometimes I fight for time. I fight every day, in every exam room, for every graying muzzle. When I fight for time, sometimes I win for awhile, but I will always eventually and inevitably lose.
This has been an intellectual exercise, but it hasn’t just been an intellectual exercise. Sure, it was a mad hunt by a man careening after an unknown to satisfy his own curiosity. But the curiosity is fueled by more than professional interest, intellectual novelty, and a congenital predisposition to follow the dopamine.
I have thousands of patients, and it is quite likely that I will outlive every single one of them. These patients are the pets my family and friends and neighbors dearly love. They are my own as well. My hypothesis may yet be proven false, but my raisons d’etre are tangible and irrefutable. I want to help my patients, the ones loved by the people in my community, to live longer and to live better.
Maybe it fenofibrate, maybe it’s some other PPAR agonist, and maybe it’s something else entirely. But if there’s a pill that helps my patients to live longer and to live better, I want to know what’s in it.
Dogs develop most of the same age-related diseases we do - cancer, osteoarthritis, cognitive dysfunction, heart disease - at roughly proportional points in their lifespan. They share our environment, eat food derived from our food, breathe our air, absorb our stress. As translational models go, they’re about as good as it gets without enrolling your neighbor in a clinical trial.
In researching her Twitter/X for clues, I learned that she was engaged last summer. I didn’t look for a marriage announcement or anything associated with it because, well, it would’ve made be feel like a creep and a gossip columnist. If that means I’m missing something crucial to the puzzle, so be it. The result is that I’ll split the difference of possible address and use “Ms.”
Which is, perhaps notably, the the next generation of Laura Deming’s Longevity Fund. Ms. Halioua previously served as Ms. Deming’s Chief of Staff.
Just rolls right off the tongue, doesn’t it?
Although if dogs live longer, that is admittedly good for my business.
I’m like 50-60% sure, which is about about five standard deviations lower than I’m usually comfortable with when I publish something
For the purposes of this article, I’m assuming that Loyal isn’t in the business of defrauding the public, potential investors, or regulators with false statements in media appearances and press releases. Besides that, this would be zero fun if my conclusion was “they’re all lying and it’s rapamycin!”
Who describes herself as “having six names, all of them hyphenated,” which is just a great phrase I wanted to note.
In one tweet, that I’ve since lost and can’t find, she talks about finding BBs in her dog, and said something along the lines of “the case for human longevity dwindles by the minute.” I’d like to think she’s the one who’s actually that drily funny.
Using latent Dirichlet allocation, I would guess.
Raises the dough. Get it?
Worth noting that fenofibrate is four-for-five on that statement.
The name did him in, I’m sure of it. The (obviously) Canadian owners named him Maple because “he’s so sweet.” And Maple took that to heart. …and pancreas.
This was a great investigative deep dive. Enjoyed the read. They are speaking to Senior Dog Vets soon
Wow doctor, thank you for this scientific exploration full of interesting facts. Interestingly, here in Brazil we use fibrates a lot for hyperlipidemia; I wonder if endocrinologists already knew about this? I hope to find more new information from this research! And congratulations on the text!